Neozyme Corp. (Neozyme I) announced this week that its shareholders approved andadopted the company's plan of complete liquidation and dissolution. Shareholders of recordin the Cambridge, Mass., company (NASDAQ:NEOZ) were to receive $16.97 per share in thedistribution on Tuesday, the day the stock was to be delisted.

Neozyme was formed by Genzyme Corp. (NASDAQ:GENZ) to accelerate the research anddevelopment of several specific health-care products. Genzyme has now brought back all ofthose product development programs.